Company intelligence
Genchrome
🧬Licensing & Business Development Activities. We connect #pharma, #biotech, and #VCs with compelling deal opportunities
About Genchrome
Supporting Biotech on their Commercialisation Pathway to Maximise Value from Early Clinical Development to Launch. With Genchrome's team of experienced pharmaceutical experts, we provide commercial & access support to biotech all along the lifecycle from preclinical, phase I,II,II to launch. 🧬 Our Vision - Throughout our experience, we noticed 3 main trends: 1. Nearly half of biotech launches underperformed. 2. Launch Pioneers, despite high level of innovation are overall less successful than established market innovators 3. New biotech launching themselves generally achieve lower sales than in partnership with pharma With our team of international experts with strong pharmaceutical expertise, we want to help you avoid making these mistakes. What We Do: - New Product Launch - Launch Planning - Portfolio Planning - BD and M&A - Payers - Pharma Partnerships Our Fields Of Expertise From Pre-launch To Launch: - Orphan - Neurology - Hemato-Oncology - Oncology - Biosimilars - Hematology - Infectiology - Immunology & Inflammation - Cardiovascular - Nephrology - Ophtalmology For more information, please contact us at: contact@genchrome.com
Verified activity
Signals from Genchrome
3 published signals
Research & Knowledge
Genchrome noted that Revolution Medicines presented Phase 3 results for Daraxonrasib at the American Society of Clinical Oncology (ASCO) meeting, which received a standing ovation and was published in the New England Journal of Medicine.
Reported by Caroline BOULLIAT
Legal & Regulatory
Genchrome announced that Daraxonrasib is now approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
Reported by Caroline BOULLIAT
Customers & Market
Genchrome estimated sales for Atopic Dermatitis (AD) to exceed $12B with Dupixent as the leading company.
Reported by Genchrome